Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Reiser

Showing results (271-280 of 285) with videos related to

Pageof 29
Sort By:
Journal of Cataract and Refractive Surgery|August 18, 2005
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomyMelvin A Sarayba, Neda Shamie, B J Reiser, et al.
Journal of Molecular and Cellular Cardiology|May 20, 2015
Losartan treatment attenuates tumor-induced myocardial dysfunctionSarah C W Stevens, Markus Velten, Dane J Youtz, et al.
JMIR Formative Research|September 27, 2023
Internet-Delivered Cognitive Behavioral Therapy Tailored to Spouses and Significant Others of Public Safety Personnel: Formative Evaluation StudyHeather D Hadjistavropoulos, Sarah J Reiser, Janine D Beahm, et al.
Gene Therapy|January 14, 2012
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cellsC Goyvaerts, K De Groeve, J Dingemans, et al.
The Journal of Clinical Investigation|September 24, 1999
Fibroblast growth factor-2 mediates pressure-induced hypertrophic responseJ E Schultz, S A Witt, M L Nieman, et al.
Science Translational Medicine|December 20, 2023
Lesion level-dependent systemic muscle wasting after spinal cord injury is mediated by glucocorticoid signaling in miceMarkus E Harrigan, Angela R Filous, Christopher P Vadala, et al.
Journal of Medicinal Chemistry|April 1, 1990
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activitiesT K Morgan, R Lis, W C Lumma, et al.
Journal of Medicinal Chemistry|May 1, 1987
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agentsW C Lumma, R A Wohl, D D Davey, et al.
European Journal of Clinical Investigation|March 19, 2008
Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failureS Müller-Krebs, L P Kihm, B Zeier, et al.
Human Molecular Genetics|October 21, 2005
A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathyKathryn M Meurs, Ximena Sanchez, Ryan M David, et al.
Pageof 29

Showing results (271-280 of 285) with videos related to

Sort By:
Pageof 29
Journal of Cataract and Refractive Surgery|August 18, 2005
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomyMelvin A Sarayba, Neda Shamie, B J Reiser, et al.
Journal of Molecular and Cellular Cardiology|May 20, 2015
Losartan treatment attenuates tumor-induced myocardial dysfunctionSarah C W Stevens, Markus Velten, Dane J Youtz, et al.
JMIR Formative Research|September 27, 2023
Internet-Delivered Cognitive Behavioral Therapy Tailored to Spouses and Significant Others of Public Safety Personnel: Formative Evaluation StudyHeather D Hadjistavropoulos, Sarah J Reiser, Janine D Beahm, et al.
Gene Therapy|January 14, 2012
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cellsC Goyvaerts, K De Groeve, J Dingemans, et al.
The Journal of Clinical Investigation|September 24, 1999
Fibroblast growth factor-2 mediates pressure-induced hypertrophic responseJ E Schultz, S A Witt, M L Nieman, et al.
Science Translational Medicine|December 20, 2023
Lesion level-dependent systemic muscle wasting after spinal cord injury is mediated by glucocorticoid signaling in miceMarkus E Harrigan, Angela R Filous, Christopher P Vadala, et al.
Journal of Medicinal Chemistry|April 1, 1990
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activitiesT K Morgan, R Lis, W C Lumma, et al.
Journal of Medicinal Chemistry|May 1, 1987
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agentsW C Lumma, R A Wohl, D D Davey, et al.
European Journal of Clinical Investigation|March 19, 2008
Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failureS Müller-Krebs, L P Kihm, B Zeier, et al.
Human Molecular Genetics|October 21, 2005
A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathyKathryn M Meurs, Ximena Sanchez, Ryan M David, et al.
Pageof 29